AAAAAA

   
Results: 1-11 |
Results: 11
DOSE-DEPENDENT CSF ACETYLCHOLINESTERASE INHIBITION BY SDZ-ENA-713 IN ALZHEIMERS-DISEASE
Authors: CUTLER NR POLINSKY RJ SRAMEK JJ ENZ A JHEE SS MANCIONE L HOURANI J ZOLNOUNI P
Citation: Nr. Cutler et al., DOSE-DEPENDENT CSF ACETYLCHOLINESTERASE INHIBITION BY SDZ-ENA-713 IN ALZHEIMERS-DISEASE, Acta neurologica Scandinavica, 97(4), 1998, pp. 244-250
2 RAPID-DOSE TITRATIONS OF SERTINDOLE IN PATIENTS WITH SCHIZOPHRENIA
Authors: SRAMEK JJ MACK RJ AWNI W HOURANI J JHEE SS BARTO S CUTLER NR
Citation: Jj. Sramek et al., 2 RAPID-DOSE TITRATIONS OF SERTINDOLE IN PATIENTS WITH SCHIZOPHRENIA, Journal of clinical psychopharmacology, 17(5), 1997, pp. 419-422
A BRIDGING STUDY OF LU-25-109 IN PATIENTS WITH PROBABLE ALZHEIMERS-DISEASE
Authors: SRAMEK JJ FORREST M MENGEL H JHEE SS HOURANI J CUTLER NR
Citation: Jj. Sramek et al., A BRIDGING STUDY OF LU-25-109 IN PATIENTS WITH PROBABLE ALZHEIMERS-DISEASE, Life sciences, 62(3), 1997, pp. 195-202
ESTABLISHING THE MAXIMUM TOLERATED DOSE OF LESOPITRON IN PATIENTS WITH GENERALIZED ANXIETY DISORDER - A BRIDGING STUDY
Authors: SRAMEK JJ FRESQUET A MARIONLANDAIS G HOURANI J JHEE SS MARTINEZ L JENSEN CM BOLLES K CARRINGTON AT CUTLER NR
Citation: Jj. Sramek et al., ESTABLISHING THE MAXIMUM TOLERATED DOSE OF LESOPITRON IN PATIENTS WITH GENERALIZED ANXIETY DISORDER - A BRIDGING STUDY, Journal of clinical psychopharmacology, 16(6), 1996, pp. 454-458
BRIDGING STUDY OF ILOPERIDONE IN SCHIZOPHRENIC INPATIENTS
Authors: CUTLER NR SHIPLEY JE VARAKLIS J HOURANI J JHEE SS SRAMEK JJ
Citation: Nr. Cutler et al., BRIDGING STUDY OF ILOPERIDONE IN SCHIZOPHRENIC INPATIENTS, Psychopharmacology bulletin, 32(3), 1996, pp. 428-428
THE SAFETY AND TOLERANCE OF XANOMELINE TARTRATE IN PATIENTS WITH ALZHEIMERS-DISEASE
Authors: SRAMEK JJ HURLEY DJ WARDLE TS SATTERWHITE JH HOURANI J DIES F CUTLER NR
Citation: Jj. Sramek et al., THE SAFETY AND TOLERANCE OF XANOMELINE TARTRATE IN PATIENTS WITH ALZHEIMERS-DISEASE, Journal of clinical pharmacology, 35(8), 1995, pp. 800-806
SAFETY AND TOLERABILITY OF CI-979 IN PATIENTS WITH ALZHEIMERS-DISEASE
Authors: SRAMEK JJ SEDMAN AJ REECE PA HOURANI J BOCKBRADER H CUTLER NR
Citation: Jj. Sramek et al., SAFETY AND TOLERABILITY OF CI-979 IN PATIENTS WITH ALZHEIMERS-DISEASE, Life sciences, 57(5), 1995, pp. 503-510
A BRIDGING (SAFETY TOLERANCE) STUDY OF BESIPIRDINE HYDROCHLORIDE IN PATIENTS WITH ALZHEIMERS-DISEASE
Authors: SRAMEK JJ VIERECK C HUFF FJ WARDLE T HOURANI J STEWART JA CUTLER NR
Citation: Jj. Sramek et al., A BRIDGING (SAFETY TOLERANCE) STUDY OF BESIPIRDINE HYDROCHLORIDE IN PATIENTS WITH ALZHEIMERS-DISEASE, Life sciences, 57(12), 1995, pp. 1241-1248
SAFETY AND TOLERANCE OF THE MUSCARINIC AGONIST CI-979
Authors: CUTLER NR SRAMEK JJ SEIFERT RD HOURANI J REECE PA BOCKBRADER H SEDMAN AJ
Citation: Nr. Cutler et al., SAFETY AND TOLERANCE OF THE MUSCARINIC AGONIST CI-979, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 174-174
MAXIMALLY TOLERATED DOSE OF THE MUSCARINIC AGONIST CI-979 IN ALZHEIMERS-DISEASE (AD)
Authors: CUTLER NR SRAMEK JJ SEIFERT RD HOURANI J REECE PA BOCKBRADER H SEDMAN AJ WARDLE TS
Citation: Nr. Cutler et al., MAXIMALLY TOLERATED DOSE OF THE MUSCARINIC AGONIST CI-979 IN ALZHEIMERS-DISEASE (AD), Biological psychiatry, 35(9), 1994, pp. 628-628
SAFETY, TOLERANCE, PHARMACOKINETIC AND RBC CHOLINESTERASE ACTIVITY OFMDL-73,745
Authors: CUTLER NR SEIFERT RD SRAMEK JJ SCHLEMAN MM WARDLE TS HOURANI J
Citation: Nr. Cutler et al., SAFETY, TOLERANCE, PHARMACOKINETIC AND RBC CHOLINESTERASE ACTIVITY OFMDL-73,745, Biological psychiatry, 35(9), 1994, pp. 680-680
Risultati: 1-11 |